Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug

Loading news article.

Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug | WAPE

Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug

Article summary

Related companies

Comments —